Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Novartis investigational oral -2-

06/11/2021 | 03:00am EDT

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

   1. Jang JH, et al. Iptacopan Effectively Controls Intra- And Extravascular 
      Hemolysis And Leads To Durable Hemoglobin Increase In Patients With 
      Treatment-Naïve PNH. Abstract presented at the 26th Annual Congress 
      of the European Hematology Association (EHA) 2021. 
 
   2. Risitano AM. Anti-Complement Treatment in Paroxysmal Nocturnal 
      Hemoglobinuria: Where we Stand and Where we are Going. Transl Med UniSa 
      2014;8:43--52. 
 
   3. Debureaux P, et al. Hematological Response to Eculizumab in Paroxysmal 
      Nocturnal Hemoglobinuria: Application of a Novel Classification to 
      Identify Unmet Clinical Needs and Future Clinical Goals. Blood 
      2019;134(Suppl 1):3517. 
 
   4. Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral 
      factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal 
      haemoglobinuria and active haemolysis: an open-label, single-arm, phase 
      2, proof-of-concept trial. Lancet Haematol. Published online 2021. 
      doi:10.1016/S2352-3026(21)00028-4.. 
 
   5. Novartis. Novartis investigational oral therapy iptacopan (LNP023) 
      receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric 
      Disease Designation for C3G. Available at: 
      https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g. 
      Accessed March 2021. 
 
   6. Novartis. Data on file. 
 
   7. Schubart A, et al. Small-molecule factor B inhibitor for the treatment of 
      complement-mediated diseases. Proc Natl Acad Sci U S A 
      2019;116(16):7926--7931. 
 
   8. Merle NS, et al. Complement system part II: role in immunity. Front 
      Immunol 2015;6:257. 
 
   9. Novartis press release. Novartis announces iptacopan met Phase II study 
      primary endpoint in rare kidney disease IgA nephropathy (IgAN). Available 
      at: 
      https://www.novartis.com/news/media-releases/novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-rare-kidney-disease-iga-nephropathy-igan. 
      Accessed June 2021. 
 
  10. Novartis press release. Novartis announces new interim analysis Phase II 
      data for iptacopan in rare kidney disease C3 glomerulopathy (C3G). 
      Available at: 
      https://www.novartis.com/news/media-releases/novartis-announces-new-interim-analysis-phase-ii-data-iptacopan-rare-kidney-disease-c3-glomerulopathy-c3g. 
      Accessed June 2021. 
 
  11. Hill A, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 
      2017;3:17028. 
 
  12. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement 
      system: recent insights and novel anticomplement strategies. Adv Exp Med 
      Biol. 2013;735:155--72. 
 
  13. Risitano AM and Rotoli B. Paroxysmal nocturnal hemoglobinuria: 
      pathophysiology, natural history and treatment options in the era of 
      biological agents. Biologics 2008;2(2):205--222. 
 
  14. Hill A, et al. Eculizumab prevents intravascular hemolysis in patients 
      with paroxysmal nocturnal hemoglobinuria and unmasks low-level 
      extravascular hemolysis occurring through C3 opsonization. Haematologica 
      2010;95(4):567--573. 
 
  15. Schrezenmeier H, et al. Baseline characteristics and disease burden in 
      patients in the International Paroxysmal Nocturnal Hemoglobinuria 
      Registry. Haematologica 2014;99(5):922--929. 
 
  16. Novartis. Novartis received European Medicines Agency (EMA) PRIME 
      designation for iptacopan (LNP) in C3 glomerulopathy (C3G). Available 
      at: https://www.novartis.com/news/media-releases/novartis-received-europe 
      an-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy 
      -c3g. Accessed March 2021. 
 
  17. Novartis. Novartis announces European Medicines Agency (EMA) has granted 
      orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN). 
      Available at: 
      https://www.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan. 
      Accessed March 2021. 

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

 
Anja von Treskow                      Michael Billings 
 Novartis Strategy & Financial         Novartis Oncology Communications 
 Communications                        +1 862 778 8656 (direct) 
 +41 79 392 8697 (mobile)              +1 201 400 1854 (mobile) 
 anja.von_treskow@novartis.com         michael.billings@novartis.com 
 Julie Masow                           Phil McNamara 
 Novartis US External Communications   Novartis Cardio-Renal- Metabolic Communications 
 +1 862 579 8456 (mobile)              +1 862 778 0218 (direct) 
 julie.masow@novartis.com              +1 862 274 5255 (mobile) 
                                       philip.mcnamara@novartis.com 
 

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

 
Central                                 North America 
Samir Shah             +41 61 324 7944  Sloan Simpson  +1 862 778 5052 
Thomas Hungerbuehler   +41 61 324 8425 
Isabella Zinck         +41 61 324 7188 
 
 
 

(END) Dow Jones Newswires

June 11, 2021 03:00 ET (07:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
NOVARTIS AG -0.24% 85.72 Delayed Quote.2.47%
All news about NOVARTIS AG
06/18NOVARTISá : Study Shows Improved Motor Function in Children with Spinal Muscular..
MT
06/18PRESS RELEASEá : Novartis: New Zolgensma data -3-
DJ
06/18PRESS RELEASEá : Novartis: New Zolgensma data -2-
DJ
06/18PRESS RELEASEá : Novartis: New Zolgensma data demonstrate age-appropriate develo..
DJ
06/18NOVARTISá : New Zolgensma data demonstrate age-appropriate development when used..
DJ
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
MT
06/17NOVARTIS INDIAá : Consolidated Net Profit Climbs in Fiscal Q4
MT
06/17CureVac may let contractors make rival vaccines if own shot fails -CEO
RE
06/17CureVac may let contractors make rival vaccines if own shot fails - CEO
RE
06/17NOVARTIS AGá : Deutsche Bank keeps its Buy rating
MD
More news
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,7x
Yield 2021 3,53%
Capitalization 208 B 209 B -
EV / Sales 2021 4,48x
EV / Sales 2022 4,19x
Nbr of Employees 110 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 106,54 $
Last Close Price 92,83 $
Spread / Highest target 60,4%
Spread / Average Target 14,8%
Spread / Lowest Target -5,68%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.47%208 642
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
ABBVIE INC.5.57%199 795
ELI LILLY AND COMPANY29.44%198 668